ADN LAB
ActiveSummary
ADN LAB has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €150,554 and a net result of €80,716. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 20-03-2024 Normal situation
- Activity
- “Toutes opérations se rapportant directement ou indirectement à l’analyse médicale,la biologie clinique et toutes…” (deed in French)From the articles, 10 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.357.689.720 4041 Herstal, since 20-03-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 13-10-2025
Board and ownership
- NIZET Adrien Christophe DanielDirector · since 20-03-2024
- NIZET Adrien Christophe Daniel100 sharesdeed of 22-03-2024
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Turnover
- €0
- Profit
- €80,716
- ▲ 20.8%
- Equity
- €150,554
- ▲ 116%
- Total assets
- €277,915
- ▲ 29.0%
Score breakdownraises riskFounded in 2024lowers riskSize: turnover €0, total assets €277,915Liquidity: current ratio 3.20, cash €86,173No main activity registeredShow the evidence
Checked score
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 47% of them on solvency, 75% on liquidity, 90% on profitability and 93% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 2 accounts on average 29 days before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 07-07-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2025 is 26% higher than in 2024.
Investments
| Item | 2024 | 2025 |
|---|---|---|
| Tangible fixed assets | €134,656 | €1,626 |
| Depreciation and write-downs of the year | €4,954 | €27,591 |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Turnover70 | - | €0 | - |
| Goods, raw materials, services and sundry goods60/61 | - | €0 | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €4,954 | €27,591 | ▲ 457% |
| Other operating charges640/8 | €242 | €167 | ▼ 31.0% |
| Gross operating margin9900 | €91,233 | €135,826 | ▲ 48.9% |
| Operating profit (loss)9901 | €86,036 | €108,068 | ▲ 25.6% |
| Financial income75/76B | €5 | - | - |
| Recurring financial income75 | €5 | - | - |
| Financial charges65/66B | €695 | €3,590 | ▲ 417% |
| Recurring financial charges65 | €695 | €3,590 | ▲ 417% |
| Profit (loss) for the period before taxes9903 | €85,347 | €104,478 | ▲ 22.4% |
| Income taxes67/77 | €18,509 | €23,762 | ▲ 28.4% |
| Profit (loss) for the period9904 | €66,838 | €80,716 | ▲ 20.8% |
| Profit (loss) for the period to be appropriated9905 | €66,838 | €80,716 | ▲ 20.8% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €215,455 | €277,915 | ▲ 29.0% |
| Fixed assets21/28 | €129,702 | €103,737 | ▼ 20.0% |
| Tangible fixed assets22/27 | €129,702 | €103,737 | ▼ 20.0% |
| Plant, machinery and equipment23 | €2,489 | €1,973 | ▼ 20.7% |
| Furniture and vehicles24 | €127,213 | €101,763 | ▼ 20.0% |
| Current assets29/58 | €85,754 | €174,179 | ▲ 103% |
| Amounts receivable within one year40/41 | €67,614 | €87,645 | ▲ 29.6% |
| Trade receivables40 | €67,321 | €87,645 | ▲ 30.2% |
| Other amounts receivable41 | €293 | €0 | ▼ 100% |
| Cash at bank and in hand54/58 | €17,781 | €86,173 | ▲ 385% |
| Deferred charges and accrued income490/1 | €359 | €361 | ▲ 0.5% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €215,455 | €277,915 | ▲ 29.0% |
| Equity10/15 | €69,838 | €150,554 | ▲ 116% |
| Contributions10/11 | €3,000 | €3,000 | = |
| Profit (loss) carried forward14 | €66,838 | €147,554 | ▲ 121% |
| Amounts payable17/49 | €145,617 | €127,361 | ▼ 12.5% |
| Amounts payable after more than one year17 | €96,680 | €72,590 | ▼ 24.9% |
| Financial debts170/4 | €96,680 | €72,590 | ▼ 24.9% |
| Amounts payable within one year42/48 | €48,612 | €54,509 | ▲ 12.1% |
| Current portion of amounts payable after more than one year42 | €25,244 | €26,063 | ▲ 3.2% |
| Financial debts43 | €643 | €438 | ▼ 31.9% |
| Credit institutions430/8 | €643 | €438 | ▼ 31.9% |
| Trade debts44 | €817 | €842 | ▲ 3.1% |
| Suppliers440/4 | €817 | €842 | ▲ 3.1% |
| Taxes, remuneration and social security45 | €21,909 | €27,162 | ▲ 24.0% |
| Taxes450/3 | €19,859 | €25,112 | ▲ 26.5% |
| Remuneration and social security454/9 | €2,050 | €2,050 | = |
| Other amounts payable47/48 | €0 | €3 | - |
| Accrued charges and deferred income492/3 | €325 | €263 | ▼ 19.1% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €66,838 | €80,716 | ▲ 20.8% |
| + Depreciation and write-downs630 | €4,954 | €27,591 | ▲ 457% |
| Operating cash flow (approximation) | €71,792 | €108,307 | ▲ 50.9% |
| Investment in fixed assets (approximation) | - | -€1,626 | - |
| Change in cash | - | €68,392 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 39,278 companies had the same profile as ADN LAB has now. Two years later, 95.8% were still going and 1.8% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of ADN LAB itself is lower: 0.1% within 12 months. It rests on far more data about ADN LAB than the profile alone.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for ADN LAB. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Board & ownership
Directors
Owners and capital
Shareholders
- NIZET Adrien Christophe Daniel 100 shares (100%) · €3,000 in cash
Capital transactions
- 22-03-2024 Incorporation · €3,000 · 100 shares
Articles of association
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- 1 director
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
Articles of association, deed of 22-03-2024 (in French)
Network & group
ADN LAB shares no director with another company.
Connections & network
1 current directorThe network starts from the directors of ADN LAB. Every other company they run is a node.
Timeline
Deeds, filings and financial milestones
22-03
Gazette deed
IncorporationFounding capital of €3,000, 100 shares · Founder: NIZET Adrien Christophe Daniel (comparant requérant la constitution) · Appointment: NIZET Adrien Christophe Daniel (director)5 points ▸
- Founder, NIZET Adrien Christophe Daniel (comparant requérant la constitution)
- Founding capital, €3,000, 100 shares
- 100 shares
- Registered office clause, rue du Nouveau Siège 83, 4041 Milmort
- Director appointment, NIZET Adrien Christophe Daniel (director (not named in the articles))
- The deed holds 2 more points.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
10 activities
- Toutes opérations se rapportant directement ou indirectement à l’analyse médicale,la biologie clinique et toutes activités médicales,paramédicales,pharmaceutiques,et techniques s’y rapportant,ainsi que la formation,le recrutement,et le placement de toutes personnes susceptibles d’exercer les compétences ci-dessus
- Les activités de pharmacologie,l'exploitation de pharmacies,l'importation,l'exportation,la fabrication,la distribution,le commerce,sous toutes ses formes,y compris le courtage et la représentation de tous produits et accessoires en pharmacie,phytopharmacie,bandagisterie,parfumerie et droguerie,ainsi que des appareils médicaux,d'analyse,de contrôles et de soins
- La société pourra entamer tous programmes de recherches relatives à de nouveaux produits ou procédés ainsi qu’acquérir,exploiter et accorder tous brevets,licences ou marques
- L'achat,l'échange,la vente,la prise en location et en sous location,ainsi que la cession en location et en sous location,le tout avec ou sans option d'achat,l'exploitation et l'entretien de maisons,appartements,bureaux,magasins,fonds de commerce,terrains,terres et domaines,et de manière générale,de tous biens immobiliers,ainsi que toutes opérations de financement
- Elle pourra ériger toutes constructions pour son compte ou pour compte de tiers,en tant que maître de l'ouvrage ou entrepreneur général,et effectuer,éventuellement aux biens immobiliers,des transformations et mises en valeur ainsi que l'étude et l'aménagement de lotissements y compris la construction de routes et égouts
- Souscrire des engagements en tant que conseiller en construction(études de génie civil et des divers équipements techniques des immeubles)
- Acheter tous matériaux
- Signer tous contrats d'entreprises qui seraient nécessaires
- Réaliser toutes opérations de change,commission et courtage,ainsi que la gérance d'immeubles
- Elle peut acheter,exploiter et construire tant pour elle même que pour des tiers,par location ou autrement,tous parkings,garages,station service et d'entretien
Invoicing and payment
Financial year and general meeting
Accounts at the NBBSites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 62071B0728/00N003 | Wallonia | 749 m² | 1 · 89 m² | 8.6 m · 2 |